Abnormalities of IL-12 Family Cytokine Pathways in Autosomal Dominant Polycystic Kidney Disease Progression DOI Creative Commons
Corina Daniela Ene,

Ilinca Nicolae,

Cristina Căpușă

et al.

Medicina, Journal Year: 2024, Volume and Issue: 60(12), P. 1971 - 1971

Published: Nov. 30, 2024

Background and Objectives: Autosomal Dominant Polycystic Kidney Disease (ADPKD) is the most frequent genetic renal disease with a complex physiopathology. More more studies sustain that inflammation plays crucial role in ADPKD pathogenesis progression. We evaluated IL-12 involvement pathophysiology by assessing serum levels of its monomers heterodimers. Materials Methods: A prospective case-control study was developed included 66 subjects control group 40 healthy subjects. The diagnosis based on familial history clinical imagistic exams. eGFR > 60 mL/min/1.73 mp, no hematuria or other disorders, stable blood pressure last 6 months. tested p40 p35 heterodimers p70, IL-23, IL 35, assessed ELISA method. Results: family programming abnormal patients. IL-12p70, IL-12p40, IL-23 secretion increased, while IL-12p35 IL-35 decreased compared to control. had progressive increase correlated immune response amplification, decrease eGFR, an TKV, albuminuria. On hand, were negatively CRP albuminuria positively advanced ADPKD. Conclusions: present investigated cytokine members’ pathogenesis, enriching our understanding common disorder.

Language: Английский

A Combination Approach to Improving Prognostication in Autosomal Dominant Polycystic Kidney Disease DOI
Sayna Norouzi, Pranav S. Garimella

Clinical Journal of the American Society of Nephrology, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 11, 2025

1Division of Nephrology, Loma Linda University, Linda, California 2Division Nephrology and Hypertension, UC San Diego, Correspondence: Dr. Pranav S. Garimella, email: [email protected] See related article, "Integrated Use Autosomal Dominant Polycystic Kidney Disease Prediction Tools Risk Prognostication," on pages XXX–XXX.

Language: Английский

Citations

0
Polycystic Kidney Disease in Children: The Current Status and the Next Horizon DOI
Melissa A. Cadnapaphornchai, Katherine MacRae Dell, Charlotte Gimpel

et al.

American Journal of Kidney Diseases, Journal Year: 2025, Volume and Issue: unknown

Published: March 1, 2025

Language: Английский

Citations

0
Management of Anterior Mediastinal Hodgkin’s Lymphoma in Polycystic Kidney Disease: A Case Report DOI Open Access
Andrew Wang, Emily Heath,

A. Rashid Dar

et al.

Cureus, Journal Year: 2025, Volume and Issue: unknown

Published: April 1, 2025

Language: Английский

Citations

0
Diagnosis of Autosomal Dominant Polycystic Kidney Disease in a 66-Year-Old Patient With a Genotype-Phenotype Mismatch DOI Open Access

Gautam Agrawal,

Bhawna Agarwal,

Pallavi Shirsat

et al.

Cureus, Journal Year: 2025, Volume and Issue: unknown

Published: April 4, 2025

Language: Английский

Citations

0
Autosomal dominant polycystic kidney disease: an overview of recent genetic and clinical advances DOI Creative Commons

Abdul Hamid Borghol,

Mikhail D. Antoun,

Christian Hanna

et al.

Renal Failure, Journal Year: 2025, Volume and Issue: 47(1)

Published: April 23, 2025

Autosomal Dominant Polycystic Kidney Disease (ADPKD) is the most common inherited kidney disease, characterized by progressive development of multiple cysts, leading to a gradual decline in function. ADPKD also fourth cause failure (KF) adults. In addition manifestations, associated with various extrarenal features, including liver cardiovascular abnormalities, intracranial aneurysms, and chronic pain significant impact on patients' quality life. While several disease-modifying agents have been tested ADPKD, tolvaptan remains only approved drug US Food Drug Administration. The Mayo Imaging Classification currently practical tool for predicting rate disease progression ADPKD. This review provides comprehensive overview focusing its genetics, pathophysiology, clinical presentation, management, prognostic tools. Advances diagnostic imaging genetic testing improved early detection allowing better classification patients prediction KF. discusses current therapeutic approaches tolvaptan, vasopressin V2-receptor antagonist. Additionally, we address specific issues children pregnant individuals Despite substantial progress understanding there large need additional effective treatments markers provide more personalized care these patients.

Language: Английский

Citations

0
Response to "Understanding Familial Variability in ADPKD: A Comprehensive Approach Integrating Genetics, Hormones, and Lifestyle for Tailored Management" DOI Creative Commons

Elhussein A. Elhassan,

Gianpiero L. Cavalleri, Peter J. Conlon

et al.

Kidney International Reports, Journal Year: 2024, Volume and Issue: 10(1), P. 273 - 274

Published: Oct. 28, 2024

Language: Английский

Citations

0
Citrate in autosomal dominant polycystic kidney disease: biomarker or therapeutic agent? DOI
Daniel Ribeiro da Rocha, Ana Cristina Carvalho de Matos, Ita Pfeferman Heilberg

et al.

Current Opinion in Nephrology & Hypertension, Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 13, 2024

This review highlights the latest findings regarding hypocitraturia in autosomal dominant polycystic kidney disease (ADPKD), from both experimental and clinical studies, exploring underlying pathophysiology potential therapeutic approach. Experimental studies have shown that lodging of microcrystals tubules can trigger cyst formation growth (PKD). ADPKD patients are prone to developing early stages, which could predispose calcium microcrystal formation. Low urinary citrate excretion has been associated with a more rapid decline eGFR poorer renal survival patients. Animal employing supplementation promising effects on preserving estimated glomerular filtration rate (eGFR) growth. Current knowledge suggests be incorporated into existing prognostic markers for progression adjuvant therapy ADPKD, but further support such hypothesis must undertaken.

Language: Английский

Citations

0
Abnormalities of IL-12 Family Cytokine Pathways in Autosomal Dominant Polycystic Kidney Disease Progression DOI Creative Commons
Corina Daniela Ene,

Ilinca Nicolae,

Cristina Căpușă

et al.

Medicina, Journal Year: 2024, Volume and Issue: 60(12), P. 1971 - 1971

Published: Nov. 30, 2024

Background and Objectives: Autosomal Dominant Polycystic Kidney Disease (ADPKD) is the most frequent genetic renal disease with a complex physiopathology. More more studies sustain that inflammation plays crucial role in ADPKD pathogenesis progression. We evaluated IL-12 involvement pathophysiology by assessing serum levels of its monomers heterodimers. Materials Methods: A prospective case-control study was developed included 66 subjects control group 40 healthy subjects. The diagnosis based on familial history clinical imagistic exams. eGFR > 60 mL/min/1.73 mp, no hematuria or other disorders, stable blood pressure last 6 months. tested p40 p35 heterodimers p70, IL-23, IL 35, assessed ELISA method. Results: family programming abnormal patients. IL-12p70, IL-12p40, IL-23 secretion increased, while IL-12p35 IL-35 decreased compared to control. had progressive increase correlated immune response amplification, decrease eGFR, an TKV, albuminuria. On hand, were negatively CRP albuminuria positively advanced ADPKD. Conclusions: present investigated cytokine members’ pathogenesis, enriching our understanding common disorder.

Language: Английский

Citations

0